A mass spectrometry detection method and system for determining the concentration of formic acid in human plasma
By screening the data from the blood sample collection site and during the thawing process, the problem of external factors affecting blood samples when measuring formic acid concentration is solved, and the sample quality and detection accuracy are improved.
Patent Information
- Application Number
- CN202411368471.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-29
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-09-29
AI Technical Summary
When mass spectrometry is used to determine the concentration of formic acid in human plasma, the blood is susceptible to environmental or human factors, resulting in sample component reactions and reducing the accuracy of the detection results.
By obtaining data from the collection site and the thawing process, calculating the impact value of the collection site and the thawing risk value, generating corresponding signals, setting screening conditions for initial and final screening of blood samples, filtering samples with unqualified quality, and improving sample quality.
The quality of blood samples affected by external factors is reduced and the accuracy of mass spectrometry detection results is improved.
Smart Images

Figure CN118885948B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of mass spectrometry detection, and in particular to a mass spectrometry detection method and system for determining the concentration of formic acid in human plasma. Background Art
[0002] Mass spectrometry is a highly sensitive and specific analytical method that is widely used for the quantitative analysis of small molecules in biological samples. In the biomedical field, mass spectrometry is often used to determine the concentration of drugs, metabolites and other substances in biological fluids such as blood and urine.
[0003] At present, when using mass spectrometry to measure the concentration of formic acid in human plasma, when the blood is affected by environmental factors or some human factors, it is easy to cause the components in the blood to react, resulting in changes in the formic acid concentration in the plasma, resulting in a decrease in the accuracy of the mass spectrometry detection results. Summary of the invention
[0004] The object of the present invention is to provide a mass spectrometry detection method for determining the concentration of formic acid in human plasma, so as to solve the above-mentioned problems.
[0005] The purpose of the present invention can be achieved by the following technical solutions:
[0006] A mass spectrometry detection method for determining the concentration of formic acid in human plasma comprises the following steps:
[0007] Step 1: Obtain the data of the collected part and calculate the influence value of the collected part; wherein the data of the collected part includes the red value of the collected part;
[0008] Step 2: According to the collection site influence value, determine the influence of the state of the collection site on the blood sample, and generate a collection site state signal; wherein the collection site state signal includes a collection site high risk signal and a collection site low risk signal;
[0009] Step 3: Based on the normal signal of the collection site, the thawing data of the blood sample is obtained, and the thawing risk value of the blood sample is calculated; wherein the thawing data includes the thawing temperature and the thawing time;
[0010] Step 4: judging the stability of the blood sample during the thawing process according to the blood sample thawing risk value, and generating a blood sample thawing risk signal; wherein the blood sample thawing risk signal includes a blood sample thawing high risk signal and a blood sample thawing low risk signal;
[0011] Step 5: According to the blood sample collection data and thawing data, blood sample screening conditions are set to perform initial screening of the blood samples;
[0012] Step 6: Based on the initial screening of blood samples, obtain abnormal values of blood sample quality and conduct final screening of blood samples.
[0013] As a further solution of the present invention: in step 1, the blood collection site is evenly divided into a number of detection areas, a high-definition image of each detection area is obtained by visual sensing technology, and a red value in the RGB value of the image is obtained by image analysis software;
[0014] Calculate the absolute difference between the red value of the detection area and the standard red value to obtain the red difference value of the detection area;
[0015] Compare the red difference value of the detection area with the red difference threshold. If the red difference value of the detection area is greater than the red difference threshold, mark the detection area as an abnormal detection area.
[0016] If the red difference value of the detection area is less than or equal to the red difference threshold, the detection area is marked as a normal detection area;
[0017] Obtain the number of abnormal detection areas, calculate the ratio of the number of abnormal detection areas to the total number of detection areas, and obtain the abnormal proportion of the collected parts;
[0018] The red fluctuation value of the collection part is obtained, and the red fluctuation value of the collection part and the red abnormal value of the collection part are summed up to obtain the influence value of the collection part.
[0019] As a further solution of the present invention: in step 1, the process of acquiring the red fluctuation value of the collection part is:
[0020] The variance of the red values in all detection areas is calculated to obtain the red fluctuation value of the collection site.
[0021] As a further solution of the present invention: in step 2, the acquisition part influence value is obtained, and the acquisition part influence value is compared with the acquisition part influence threshold value, and if the acquisition part influence value is less than the acquisition part influence threshold value, a low risk signal of the acquisition part is generated;
[0022] If the acquisition site impact value is greater than or equal to the acquisition site impact threshold, a high-risk acquisition site signal is generated.
[0023] As a further solution of the present invention: in step 3, a detection cycle is set for the thawing data of the blood sample, and the detection cycle is evenly divided into a number of detection time periods; the temperature value of the blood sample during the thawing process within the detection time period is obtained by a temperature sensor and marked as the thawing temperature;
[0024] Calculate the difference between the thawing temperatures in adjacent detection periods to obtain a thawing temperature change value;
[0025] Calculate the variance of all thawing temperature change values to obtain the thawing temperature change fluctuation value of the blood sample within the thawing cycle;
[0026] All thawing temperature change values are summed up to obtain a total thawing temperature change value;
[0027] Obtaining the thawing time of the blood sample, calculating the ratio of the total thawing temperature change to the thawing time, and obtaining the thawing speed of the blood sample;
[0028] Then, the difference between the blood sample thawing speed and the blood sample thawing limit speed is calculated to obtain the blood sample thawing speed difference value;
[0029] By formula , the blood sample thawing risk value JD is calculated; where Bo represents the fluctuation value of the thawing temperature; Sc represents the difference value of the blood sample thawing speed, ax and bx are both weight coefficients, and ax+bx=1.
[0030] As a further solution of the present invention: in step 4, a blood sample thawing risk value is obtained, and the blood sample thawing risk value is compared with a blood sample thawing risk threshold, and if the blood sample thawing risk value is less than or equal to the blood sample thawing risk threshold, a blood sample thawing low risk signal is generated;
[0031] If the blood sample thawing risk value is greater than the blood sample thawing risk threshold, a blood sample thawing high risk signal is generated.
[0032] As a further solution of the present invention: in step 5, the red value of the collection site, the blood sample thawing temperature and the blood sample thawing speed of the collection object are obtained to perform a preliminary screening of the blood quality, and the screening condition can be set to one or more of the red value of the collection site, the blood sample thawing temperature and the blood sample thawing speed;
[0033] A screening condition value is preset, and the screening condition value is compared with the acquired sample data value; if the sample data value is less than the screening condition value, the blood sample is marked as a qualified blood sample.
[0034] As a further solution of the present invention: in step six, obtaining a blood sample quality abnormality value, and comparing the blood sample quality abnormality value with a blood sample quality abnormality threshold;
[0035] If the blood sample quality abnormality value is less than or equal to the blood sample quality abnormality threshold, the blood sample is marked as a high-quality blood sample.
[0036] As a further solution of the present invention: in step 6, the process of obtaining the abnormal value of blood sample quality is:
[0037] Obtain the collection site influence value and blood sample thawing risk value;
[0038] By formula , the blood sample quality abnormality value ZY is calculated; among them, CB represents the influence value of the collection site, JD represents the blood sample thawing risk value, are all weight coefficients.
[0039] A mass spectrometry detection system for determining the concentration of formic acid in human plasma, comprising:
[0040] Collection site status judgment module: according to the collection site influence value, judge the influence of the state of the collection site on the blood sample, and generate a collection site status signal; wherein the collection site status signal includes a collection site high risk signal and a collection site low risk signal;
[0041] Blood sample thawing risk value calculation module: based on the normal signal of the collection site, the thawing data of the blood sample is obtained, and the thawing risk value of the blood sample is calculated; wherein the thawing data includes the thawing temperature and the thawing time;
[0042] Blood sample thawing risk judgment module: according to the blood sample thawing risk value, judge the stability of the blood sample during the thawing process and generate a blood sample thawing risk signal; wherein the blood sample thawing risk signal includes a blood sample thawing high risk signal and a blood sample thawing low risk signal;
[0043] Initial screening module: according to the blood sample collection data and thawing data, blood sample screening conditions are set to perform initial screening of blood samples;
[0044] Final screening module: Based on the initial screening of blood samples, abnormal values of blood sample quality are obtained and the blood samples are finally screened.
[0045] Beneficial effects of the present invention:
[0046] (1) The present invention determines whether a blood sample is qualified based on the influence value of the blood sample collection site and the blood sample thawing risk value, thereby reducing the influence of external factors on the blood sample and improving the quality of the sample;
[0047] (2) The present invention sets blood sample screening conditions based on blood sample collection data and thawing data, and performs a primary screening of the blood samples; based on the primary screening of the blood samples, the blood sample quality abnormality values are obtained, and the blood samples are finally screened; by screening the blood samples, the present invention filters out blood samples of unqualified quality, thereby improving the quality of blood samples for mass spectrometry detection and also improving the accuracy of the mass spectrometry detection results. BRIEF DESCRIPTION OF THE DRAWINGS
[0048] The present invention will be further described below in conjunction with the accompanying drawings.
[0049] Figure 1 is a flowchart of Embodiment 1 of the present invention;
[0050] Figure 2 It is a flowchart of embodiment 2 of the present invention. DETAILED DESCRIPTION
[0051] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0052] Example 1: Please refer to Figure 1 As shown, the present invention is a mass spectrometry detection method for determining the concentration of formic acid in human plasma, comprising the following steps:
[0053] Step S1, collecting blood samples from the subject, storing and transporting the collected blood samples to a mass spectrometry detection site, and thawing the blood samples after arriving at the mass spectrometry detection site; after the thawing process is completed, screening the blood samples;
[0054] Step S2, pre-treating the screened blood sample to extract formic acid compounds in the blood; wherein the pre-treatment operation includes but is not limited to protein precipitation, solid phase extraction, derivatization reaction, etc.;
[0055] Step S3, separating the extracted formic acid compound through a chromatographic column; wherein commonly used chromatographic techniques include high performance liquid chromatography and gas chromatography;
[0056] Step S4, ionizing the separated formic acid compound; wherein the ionization technology includes but is not limited to a protonated spray ion source, a chemical ionization source, etc.;
[0057] Step S5, after the formic acid compound is converted into an ion state through ionization, the ions are sent to a mass analyzer, and ions of different masses are separated according to the mass-to-charge ratio of the ions; wherein the mass analyzer includes but is not limited to a time-of-flight mass spectrometer, a quadrupole mass spectrometer, an ion trap mass spectrometer, etc.;
[0058] Step S6, the separated ions are detected by the detector and converted into electrical signals, and the collected data are processed and analyzed by the mass spectrometry data system; wherein the data processing and analysis include the generation of mass spectra, analysis and interpretation of ion peaks;
[0059] Step S7, comparing the mass spectrometry data with the formic acid compounds in the data or inferring the structure and composition of the unknown compound by fragmentation pattern analysis (such as collision induced dissociation, CID), and generating a report based on the analysis results to describe the concentration of formic acid in the sample;
[0060] In step S1, the screening of the blood sample includes the following steps:
[0061] Step 1: Obtain the data of the collection part and calculate the influence value of the collection part;
[0062] Wherein, the collected part data includes the red value of the collected part;
[0063] In some embodiments, the blood collection site is evenly divided into several detection areas, a high-definition image of each detection area is obtained by visual sensing technology, and the red value of the RGB value in the image is obtained by image analysis software;
[0064] Calculate the absolute difference between the red value of the detection area and the standard red value to obtain the red difference value of the detection area;
[0065] It should be noted that the standard red value refers to the red value in the RGB value of the normal skin image of the collected object;
[0066] Compare the red difference value of the detection area with the red difference threshold;
[0067] If the red difference value of the detection area is less than or equal to the red difference threshold, the detection area is marked as a normal detection area;
[0068] If the red difference value of the detection area is greater than the red difference threshold, the detection area is marked as an abnormal detection area;
[0069] Obtain the number of abnormal detection areas, calculate the ratio of the number of abnormal detection areas to the total number of detection areas, and obtain the abnormal proportion of the collected parts;
[0070] Obtain the red fluctuation value of the collection part, calculate the sum of the red fluctuation value of the collection part and the red abnormal value of the collection part, and obtain the influence value of the collection part;
[0071] The process of obtaining the red fluctuation value of the collected part is as follows:
[0072] The variance of the red values in all detection areas is calculated to obtain the red fluctuation value of the collection site;
[0073] Step 2: According to the collection site influence value, determine the influence of the state of the collection site on the blood sample and generate a collection site state signal;
[0074] Wherein, the acquisition part status signal includes an acquisition part high risk signal and an acquisition part low risk signal;
[0075] In some embodiments, obtaining an acquisition site influence value, and comparing the acquisition site influence value with an acquisition site influence threshold;
[0076] If the collection site influence value is less than the collection site influence threshold, a collection site low risk signal is generated; when a collection site low risk signal is received, it means that the smaller the red value difference value of the collection site is, the more normal the state of the collection site is, and the risk of the collected blood quality is also reduced;
[0077] If the collection site influence value is greater than or equal to the collection site influence threshold, a collection site high risk signal is generated; when a collection site high risk signal is received, it means that the larger the red difference value of the collection site, the more abnormal the state value of the collection site is, and the higher the risk of the collected blood quality is;
[0078] It should be noted that: when a high-risk signal is received from a collection site, if blood is collected from that collection site, abnormalities will occur in the collected blood sample, which will ultimately affect the accuracy of the mass spectrometry test results, and the collection site needs to be replaced;
[0079] The technical solution of the present invention is as follows: acquiring the data of the collection site, calculating the influence value of the collection site; judging the influence of the state of the collection site on the blood sample according to the influence value of the collection site, and generating a collection site state signal; the present invention can judge the accuracy of blood collection by the red value of the collection site, reduce the influence of the state of the collection site on mass spectrometry detection during the blood collection process, and can also facilitate subsequent screening of blood samples according to the data and signals;
[0080] Step 3: Based on the normal signal of the collection site, the thawing data of the blood sample is obtained, and the thawing risk value of the blood sample is calculated;
[0081] Among them, the thawing data includes thawing temperature and thawing time;
[0082] In some embodiments, a detection cycle is set for the thawing data of the blood sample, and the detection cycle is evenly divided into a number of detection time periods; the temperature value of the blood sample during the thawing process within the detection time period is obtained by a temperature sensor and marked as the thawing temperature;
[0083] It should be noted that during the transportation of blood samples, they are usually stored at low temperatures or frozen to transfer the samples. This method is to try to keep the components of the blood samples unchanged during transportation;
[0084] Calculate the difference between the thawing temperatures in adjacent detection periods to obtain a thawing temperature change value;
[0085] Calculate the variance of all thawing temperature change values to obtain the thawing temperature change fluctuation value of the blood sample within the thawing cycle;
[0086] Further, all thawing temperature change values are summed up to obtain a total thawing temperature change value;
[0087] Obtaining the thawing time of the blood sample, calculating the ratio of the total thawing temperature change to the thawing time, and obtaining the thawing speed of the blood sample;
[0088] Then, the difference between the blood sample thawing speed and the blood sample thawing limit speed is calculated to obtain the blood sample thawing speed difference value;
[0089] It should be noted that the blood sample thawing limit speed represents the maximum speed of the blood sample during the thawing process. When the blood sample thawing speed exceeds the maximum speed, the components in the blood sample will change or be altered. In addition, the value of the blood sample thawing limit speed is set by relevant personnel in this field.
[0090] The blood sample thawing speed difference value and the thawing temperature change fluctuation value are weightedly summed to calculate the blood sample thawing evaluation value;
[0091] For example, by formula , the blood sample thawing risk value JD is calculated; where Bo represents the fluctuation value of thawing temperature; Sc represents the difference value of blood sample thawing speed, ax and bx are weight coefficients, and ax+bx=1;
[0092] It should be noted that the values of ax and bx are set by the relevant personnel according to the experimental requirements;
[0093] Step 4: judging the stability of the blood sample during the thawing process according to the blood sample thawing risk value, and generating a blood sample thawing risk signal;
[0094] Wherein, the blood sample thawing risk signal includes a blood sample thawing high risk signal and a blood sample thawing low risk signal;
[0095] In some embodiments, obtaining a blood sample thawing risk value, and comparing the blood sample thawing risk value with a blood sample thawing risk threshold;
[0096] If the blood sample thawing risk value is less than or equal to the blood sample thawing risk threshold, a blood sample thawing low risk signal is generated; when a blood sample thawing low risk signal is received, it means that the blood sample is more stable in the thawing process, the blood sample thawing risk value is smaller, and the quality of the blood sample is better;
[0097] If the blood sample thawing risk value is greater than the blood sample thawing risk threshold, a blood sample thawing high risk signal is generated; when a blood sample thawing high risk signal is received, it means that the more unstable the state of the blood sample is during the thawing process, the greater the thawing risk value of the blood sample is, and the worse the quality of the blood sample is, and the blood sample needs to be resampled;
[0098] It should be noted that: during the thawing process of blood, there are certain requirements for the thawing temperature and thawing speed. If the thawing temperature exceeds a certain range, the components in the blood sample will change, thereby causing the formic acid concentration in the plasma to change after the pretreatment of the blood sample. In addition, the thawing temperature also affects the thawing speed of the blood sample. If the blood thawing speed is too fast, it will also cause the components in the blood sample to change.
[0099] The technical solution of the present invention is as follows: based on the normal signal of the collection part, the present invention obtains the thawing data of the blood sample and calculates the thawing risk value of the blood sample; according to the thawing risk value of the blood sample, the stability of the blood sample in the thawing process is judged, and the thawing risk signal of the blood sample is generated; the present invention can judge whether there is an abnormal phenomenon in the thawing process of the blood through the data of the blood sample in the thawing process, prevent the abnormality of the blood sample in the thawing process from causing the change of the components of the blood sample, and improve the quality of the blood sample;
[0100] Step 5: According to the blood sample collection data and thawing data, blood sample screening conditions are set to perform initial screening of the blood samples;
[0101] In some embodiments, the red value of the collection site, the thawing temperature of the blood sample, and the thawing speed of the blood sample of the collection object are obtained to perform a preliminary screening of the blood quality, and the screening conditions can be set to one or more of the red value of the collection site, the thawing temperature of the blood sample, and the thawing speed of the blood sample;
[0102] Preset a screening condition value, and compare the screening condition value with the acquired sample data value;
[0103] If the sample data value is greater than or equal to the screening condition value, it means that the blood sample does not meet the initial screening condition, and the blood sample is marked as an unqualified blood sample; when the blood sample is marked as an unqualified blood sample, a secondary blood sampling can be performed on the collection object corresponding to the unqualified blood sample;
[0104] If the sample data value is less than the screening condition value, it means that the blood sample meets the initial screening condition, and the blood sample is marked as a qualified blood sample;
[0105] It should be noted that the sample data value is determined according to the set screening conditions; for example, if the screening condition is thawing speed, the sample data value is the sample thawing speed difference value, and the screening condition value is the thawing speed difference threshold;
[0106] Step 6: Based on the initial screening of the blood samples, abnormal values of blood sample quality are obtained, and the blood samples are finally screened;
[0107] In some embodiments, obtaining a blood sample quality abnormality value, and comparing the blood sample quality abnormality value with a blood sample quality abnormality threshold value;
[0108] If the blood sample quality abnormality value is less than or equal to the blood sample quality abnormality threshold, the blood sample is marked as a high-quality blood sample;
[0109] If the blood sample quality abnormality value is greater than the blood sample quality abnormality threshold, the blood sample is marked as a normal blood sample;
[0110] Among them, the process of obtaining abnormal values of blood sample quality is as follows:
[0111] Obtaining the collection site influence value and the blood sample thawing risk value, performing weighted summation on the collection site influence value and the blood sample thawing risk value, and calculating the blood sample quality abnormality value;
[0112] For example, by formula , the blood sample quality abnormality value ZY is calculated; among them, CB represents the influence value of the collection site, JD represents the blood sample thawing risk value, All are weight coefficients;
[0113] The high-quality blood samples are pre-processed, and after the pre-processing is completed, they are sent to a mass spectrometer for mass spectrometry detection, and finally the mass spectrometry detection results are output;
[0114] It should be noted that high-quality blood samples mean that during the process of blood collection, transportation and thawing, the blood samples are less affected by the outside world, the composition of the blood samples changes less, and the test results obtained after mass spectrometry are more accurate;
[0115] Technical solution of the present invention: The present invention sets blood sample screening conditions according to blood sample collection data and thawing data, and performs initial screening on the blood samples; based on the initial screening of the blood samples, abnormal blood sample quality values are obtained, and the blood samples are finally screened; the present invention filters out blood samples of unqualified quality by screening the blood samples, thereby improving the quality of blood samples for mass spectrometry detection and also improving the accuracy of the mass spectrometry detection results.
[0116] Example 2: Please refer to Figure 2As shown, the present invention is a mass spectrometry detection system for determining the concentration of formic acid in human plasma, comprising:
[0117] Data acquisition and calculation module: obtains the data of the acquisition part and calculates the impact value of the acquisition part;
[0118] Wherein, the collected part data includes the red value of the collected part;
[0119] Collection site status judgment module: according to the collection site influence value, judge the influence of the collection site status on the blood sample and generate a collection site status signal;
[0120] Wherein, the acquisition part status signal includes an acquisition part high risk signal and an acquisition part low risk signal;
[0121] Blood sample thawing risk value calculation module: based on the normal signal of the collection site, the thawing data of the blood sample is obtained, and the thawing risk value of the blood sample is calculated;
[0122] Among them, the thawing data includes thawing temperature and thawing time;
[0123] Blood sample thawing risk judgment module: according to the blood sample thawing risk value, judge the stability of the blood sample during the thawing process and generate a blood sample thawing risk signal;
[0124] Wherein, the blood sample thawing risk signal includes a blood sample thawing high risk signal and a blood sample thawing low risk signal;
[0125] Initial screening module: according to the blood sample collection data and thawing data, blood sample screening conditions are set to perform initial screening of blood samples;
[0126] Final screening module: based on the initial screening of blood samples, obtain the abnormal values of blood sample quality and conduct final screening of blood samples;
[0127] The above is a detailed description of an embodiment of the present invention, but the content is only a preferred embodiment of the present invention and cannot be considered to limit the scope of implementation of the present invention. All equivalent changes and improvements made within the scope of the present invention should still fall within the scope of the patent coverage of the present invention.
Claims
1. A mass spectrometry method for determining the concentration of formic acid in human plasma, It is characterized in that The following steps are involved: Step 1: Obtain the data of the collected part and calculate the influence value of the collected part; wherein the data of the collected part includes the red value of the collected part; Step 2: According to the collection site influence value, determine the influence of the state of the collection site on the blood sample, and generate a collection site state signal; wherein the collection site state signal includes a collection site high risk signal and a collection site low risk signal; Step 3: Obtain thawing data of the blood sample and calculate the thawing risk value of the blood sample; wherein the thawing data includes thawing temperature and thawing time; Step 4: judging the stability of the blood sample during the thawing process according to the blood sample thawing risk value, and generating a blood sample thawing risk signal; wherein the blood sample thawing risk signal includes a blood sample thawing high risk signal and a blood sample thawing low risk signal; Step 5: According to the blood sample collection site data and thawing data, blood sample screening conditions are set to perform initial screening of the blood samples; Step 6: Based on the initial screening of the blood samples, abnormal values of blood sample quality are obtained, and the blood samples are finally screened; In step 1, the blood collection site is evenly divided into several detection areas, a high-definition image of each detection area is obtained by visual sensing technology, and the red value of the RGB value in the image is obtained by image analysis software; Calculate the absolute difference between the red value of the detection area and the standard red value to obtain the red difference value of the detection area; Compare the red difference value of the detection area with the red difference threshold. If the red difference value of the detection area is greater than the red difference threshold, mark the detection area as an abnormal detection area. If the red difference value of the detection area is less than or equal to the red difference threshold, the detection area is marked as a normal detection area; Obtain the number of abnormal detection areas, calculate the ratio of the number of abnormal detection areas to the total number of detection areas, and obtain the abnormal proportion of the collected parts; Obtain the red fluctuation value of the collection part, calculate the sum of the red fluctuation value of the collection part and the red difference value of the detection area, and obtain the influence value of the collection part; In step six, obtaining a blood sample quality abnormality value, and comparing the blood sample quality abnormality value with a blood sample quality abnormality threshold; If the blood sample quality abnormality value is less than or equal to the blood sample quality abnormality threshold, the blood sample is marked as a high-quality blood sample; In step 6, the process of obtaining the abnormal value of blood sample quality is as follows: Obtain the collection site influence value and blood sample thawing risk value; By formula , the blood sample quality abnormality value ZY is calculated; among them, CB represents the influence value of the collection site, JD represents the blood sample thawing risk value, are all weight coefficients.
2. A mass spectrometry detection method for determining the concentration of formic acid in human plasma according to claim 1, It is characterized in that In step 2, the acquisition part influence value is obtained, and the acquisition part influence value is compared with the acquisition part influence threshold value. If the acquisition part influence value is less than the acquisition part influence threshold value, a low risk signal of the acquisition part is generated; If the acquisition site impact value is greater than or equal to the acquisition site impact threshold, a high-risk acquisition site signal is generated.
3. A mass spectrometry detection method for determining the concentration of formic acid in human plasma according to claim 1, It is characterized in that In step three, a detection cycle is set for the thawing data of the blood sample, and the detection cycle is evenly divided into a number of detection time periods; the temperature value of the blood sample during the thawing process within the detection time period is obtained by a temperature sensor and marked as the thawing temperature; Calculate the difference between the thawing temperatures in adjacent detection periods to obtain a thawing temperature change value; Calculate the variance of all thawing temperature change values to obtain the thawing temperature change fluctuation value of the blood sample within the thawing cycle; All thawing temperature change values are summed up to obtain a total thawing temperature change value; Obtaining the thawing time of the blood sample, calculating the ratio of the total thawing temperature change to the thawing time, and obtaining the thawing speed of the blood sample; Then, the difference between the blood sample thawing speed and the blood sample thawing limit speed is calculated to obtain the blood sample thawing speed difference value; By formula , the blood sample thawing risk value JD is calculated; where Bo represents the fluctuation value of the thawing temperature; Sc represents the difference value of the blood sample thawing speed, ax and bx are both weight coefficients, and ax+bx=1.
4. A mass spectrometry detection method for determining the concentration of formic acid in human plasma according to claim 3, It is characterized in that In step 4, a blood sample thawing risk value is obtained, and the blood sample thawing risk value is compared with a blood sample thawing risk threshold value, and if the blood sample thawing risk value is less than or equal to the blood sample thawing risk threshold value, a blood sample thawing low risk signal is generated; If the blood sample thawing risk value is greater than the blood sample thawing risk threshold, a blood sample thawing high risk signal is generated.
5. A mass spectrometry detection method for determining the concentration of formic acid in human plasma according to claim 1, It is characterized in that In step 5, the red value of the collection site, the blood sample thawing temperature and the blood sample thawing speed of the collection object are obtained to perform a preliminary screening of the blood quality, wherein the screening condition is set to be one or more of the red value of the collection site, the blood sample thawing temperature and the blood sample thawing speed; Preset a screening condition value, and compare the screening condition value with the acquired sample data value; If the sample data value is less than the screening condition value, the blood sample is marked as a qualified blood sample.
6. A mass spectrometry detection system for determining the concentration of formic acid in human plasma, It is characterized in that The detection system is used to perform a mass spectrometry detection method for determining the concentration of formic acid in human plasma as described in any one of claims 1 to 5, and the detection system comprises: Data acquisition and calculation module: obtains the acquisition part data and calculates the acquisition part influence value; wherein the acquisition part data includes the red value of the acquisition part; Collection site status judgment module: according to the collection site influence value, judge the influence of the state of the collection site on the blood sample, and generate a collection site status signal; wherein the collection site status signal includes a collection site high risk signal and a collection site low risk signal; Blood sample thawing risk value calculation module: obtains blood sample thawing data and calculates the blood sample thawing risk value; wherein the thawing data includes thawing temperature and thawing time; Blood sample thawing risk judgment module: according to the blood sample thawing risk value, judge the stability of the blood sample during the thawing process and generate a blood sample thawing risk signal; wherein the blood sample thawing risk signal includes a blood sample thawing high risk signal and a blood sample thawing low risk signal; Initial screening module: according to the blood sample collection site data and thawing data, blood sample screening conditions are set to perform initial screening of blood samples; Final screening module: Based on the initial screening of blood samples, abnormal values of blood sample quality are obtained and the blood samples are finally screened.
